benefits

Jared Bernstein: Recovery Act in Action: A Window Into a Change of Heart

April 1, 2010

For this week’s episode of Recovery Act in action, I spoke to a business owner who started out skeptical about the benefits of the Recovery Act. In fact, he was so concerned that the Act wouldn’t help the economy, he worried that the Recovery Act was “mortgaging the future.” Fast forward to the present, where the Recovery Act has created a wave of new demand for the energy efficient windows his company makes. Based on that demand, his sales have picked up such that he’s added 100 new workers, in occupations ranging from line workers to managers. “He” is Alan Levin, owner and CEO of Northeast Building Products, a Philadelphia-based manufacturer of energy-efficient windows. When the Recovery Act was passed last February, he figured it was another government program that was going to bypass the little guy. A small business like his would never see any of the benefits. “I was skeptical,” Alan told me when I reached him this week. “These numbers people were throwing around — hundreds of billions of dollars — they’re unfathomable. We see ourselves as just a little mom and pop operation and I never imagined a program like this would reach down and help the way it has.” Yet just a few months after the Act went into effect, he was getting calls for new orders generated by two different measures in the Recovery Act. One is a grant program for cities and states to do energy-efficient retrofits of public housing. The other is a program that gives homeowners a tax credit for putting in high-efficiency windows and making other energy-saving improvements to their own homes. That tax credit can put up to $1,500 straight into a homeowner’s pocket, not to mention the savings on energy bills from the windows themselves. The way Alan tells the story, the credit has had a dramatic impact on his industry. “It used to be the contractors wanted to know, ‘What’s your cheapest window?’ Now they’re asking, ‘What’s the most energy efficient window at the best price? They’re looking at value in a way they never have before.” In other words, not only are these programs providing jobs for Alan’s new hires and income for their families, they’re “greening” the market while lowering energy bills for his customers. For middle-class families feeling squeezed, those lower bills provide some much-needed relief to their budgets. In fact, this tax credit is still available, so it’s not too late to take advantage of it yourself (check out this new tool to learn about this and other Recovery Act tax benefits). You can get up to $1,500 to make your home more energy efficient, save yourself some money by cutting down on your energy bills, and maybe even put someone back to work at a business like Alan’s.

Read the full article →

Daniel Altman: A New Market for "Patient Capital"

March 29, 2010

This article was inspired by The Economist ‘s “Ideas Economy” Conference, which took place at the Haas School of Business at Berkeley last week. “Patient capital” is a crucial ingredient for two components of global economic growth: innovation and the development of poor countries. The owners of patient capital have long time horizons, meaning that they can endure the uncertain early years of an investment to reap high returns in the long term. In today’s volatile markets, patient capital can be hard to find. A new, government-backed swaps market could change that. Investments in innovation can take decades to pay off, and the uncertainty inherent in the innovative process makes it difficult to pick winners. Government already invests in innovation by funding basic research and education, but there are other opportunities that arise in the business sector — opportunities that go unfunded because private sources of finance can’t bear the risk. Most private sources either aren’t big enough to be sufficiently diversified (they can’t take on hundreds of these investments at a time), or they aren’t patient enough (their backers demand a return within a few years). The same is true of investments in development. Emerging economies are often risky environments for investors, be they foreign or domestic. These economies’ political and business cycles may be too erratic to assure a steady return, and they may have frequent crises that threaten to wipe out young ventures. Even if the returns are high — as they often are in emerging economies — private sources of finance can’t bear the risk. Some governments offer foreign aid to the countries where these opportunities arise, but they rarely invest in specific commercial ventures. Yet successful investments in both innovation and development can have positive, global effects. Innovation is a public good; its benefits accrue not just to innovators but to society as a whole, which enjoys innovation’s end products and is inspired to push the innovation process further. Likewise, rising living standards in developing countries help people around the world; they tend to correspond to lower levels of conflict and disease, and higher levels of trade and the exchange of ideas. Because of these positive spillovers, society as a whole has an interest in providing the patient capital needed to realize investments in innovation and development. So far, governments have only done so indirectly, via domestic grant programs, tax credits, trade preferences, and foreign aid. Yet a new mechanism could offer a much more targeted and fruitful way of funding productive opportunities. First, consider what is special about governments. The stable ones can plan decades in advance, even when the political leadership changes along the way. This is a much longer time horizon than most venture capitalists and private equity funds can claim. Governments are also big; they can commit billions of dollars at the stroke of a pen, as long as the spending plan matches their priorities. So far, however, governments have not fully applied the benefits of their time horizons and size to the problem of patient capital. In a government-backed swaps market, they could — and the benefits would accrue not just to investors and recipients of financing, but also to taxpayers. A swaps market is exactly what it sounds like: a market where investors swap one kind of return for another. If you’re holding an asset slated to pay a high return but with significant risks attached, you might prefer to swap it for a more stable, if lower, return. For example, you might prefer to exchange the payments owed to you on a floating rate commercial loan for the payments from a fixed-rate government bond. Of course, you may have to pay someone to make this swap with you; that amount is the price of the swap in the market. Private swaps markets are huge, with billions of dollars changing hands every day as financial institutions and other companies try to balance the risks in their portfolios. But many investments in innovation and development aren’t in the swaps markets. In fact, they’re not in any market; no investor is patient enough, and no investor can diversify enough, to take them on. Governments can change that. By offering to swap the returns on these high-risk, high-payoff investments for more stable cash flows, governments could encourage private sources of finance to fund these investments for the first time. For instance, let’s say a cashew producer in Senegal needs $5 million to build a new processing plant. The plant would have equal chances of delivering an annual return of 20 percent or going bust. If the plant is successful, though, it would also creates hundreds of jobs and be an anchor for the development of its community. So far, no one wants to invest. But a venture capital firm might be willing to put up the $5 million if, instead of the 50-50 chance of a 20 percent return after a few years, it received 7 percent per year starting now. Who would make this swap? A foreign government interested in Senegal’s development might. With a big, diversified portfolio full of investments just like this one, that government could expect a 10 percent annual return, on average, after a few years. That’s not a very long time to wait, considering government’s time horizon; what’s a few years, when you’re worried about funding Social Security until 2075? Moreover, the investment would be a quadruple winner: the cashew producer would get its plant, Senegal would develop, the venture capitalist would get a good return, and taxpayers would get an even better one. The government would not be crowding private investors out of this market; rather, it would be facilitating a new market that otherwise would not exist, and then sharing in the gains from trade. There is plenty of precedent for government’s facilitation of markets, even in the United States. The Export-Import Bank finances exports of American merchandise to countries considered too risky by private credit markets. The Federal Reserve offers liquidity to banks and acts as a lender of last resort through its discount window. In both cases, a diversified portfolio and a long time horizon make the mechanism work. In fact, both of these mechanisms have made money for the American taxpayer. Swaps markets for innovation and development would make money, too — not because they were stealing business from the private sector, but because they were opening up a set of economic opportunities that no other mechanism could provide. They’re not just win-win; they’re win-win-win-win.

Read the full article →

Cholesterol-Cutting Drugs Raise Risk of Diabetes by 9%, Researchers Find

February 17, 2010

By Michelle Fay Cortez Feb. 17 (Bloomberg) — Pfizer Inc. ’s Lipitor, AstraZeneca Plc ’s Crestor and rival drugs to lower cholesterol also boost diabetes rates by about 9 percent, according to a study that quantified a complication that doctors only recently discovered. The drugs, which generated $34 billion in 2008 sales, prevent heart attacks, strokes and death, and their benefits outweigh the diabetes risk, said lead researcher David Preiss, a research fellow at the University of Glasgow. The pills were linked to one additional case of diabetes and prevented five heart attacks and deaths for every 1,000 patients who took them for a year, he said. The researchers analyzed 13 studies of the medicines known as statins after a 2008 trial from London-based AstraZeneca unexpectedly found patients given Crestor had a 25 percent higher risk of diabetes. The new analysis involving more than 90,000 patients, published in the journal Lancet , shows the actual increase in diabetes is 9 percent, the risk is tied to the entire class of medications and the danger increases with age. “Even though there is a slight risk more than what we knew before, it’s still a reassuring message,” Preiss said in a telephone interview. “We’re not talking a huge risk at all, and what we don’t want people to do is take this as a sign to stop taking statin therapy.” Future studies and researchers conducting long-term followup should include blood-sugar reading and diabetes development, the investigators said. Patients and doctors should also be aware of the potential risk and adjust treatment if the drugs’ potential benefits no longer outweigh the risk, they said. Patients may benefit from blood-sugar monitoring during their regular medical checkups, said Chris Cannon , a cardiologist at Brigham and Women’s Hospital in Boston, in an editorial that accompanied the study. “Whilst a new risk of statins has been identified, the risk seems small and far outweighed by the benefits of this life-saving class of drugs,” he said. To contact the reporter on this story: Michelle Fay Cortez in London at mcortez@bloomberg.net

Read the full article →

Fannie Mae Bid to Sell Tax Credits Vetoed by U.S., Thwarting Goldman Sachs

November 7, 2009

By Dawn Kopecki Nov. 7 (Bloomberg) — Fannie Mae’s request to sell $2.6 billion in low-income housing tax credits would be a bad deal for taxpayers and won’t be allowed, the U.S. Treasury said. The government decided the deal would cost taxpayers more than Fannie Mae would gain from the sale, according to a letter sent to the Washington-based company yesterday. The Treasury was considering whether to let Goldman Sachs Group Inc. buy credits, which could be used to lower the firm’s tax bill. The prospect of record year-end bonus payments at Goldman Sachs had sparked criticism from lawmakers even after the securities firm repaid $10 billion from the Treasury last year plus dividends. New York-based Goldman has also benefited from Federal Reserve support and government backing on about $30 billion of debt, and was one of the largest recipients of funds from the U.S. bailout of American International Group Inc. “Every politician on Capitol Hill right now hates Goldman,” said Paul Miller , a bank analyst with FBR Capital Markets in Arlington, Virginia. “Politically, this would look really bad.” Goldman said last month it has set aside $16.7 billion for compensation so far this year, up 46 percent from the same period in 2008. Fannie Mae, which is operating under government conservatorship, has said it may not be able to use the tax credits because it hasn’t reported a profit in nine quarters. The company entered an agreement before Sept. 30 to sell the credits at a premium, partly to avoid potential writedowns, according to a Nov. 5 filing with the Securities and Exchange Commission. No Economic Sense “The proposed sale would result in a loss of aggregate tax revenues that would be greater than the savings to the federal government from a reduction in the capital contribution obligation of Treasury to Fannie Mae,” the Treasury said in the letter. “Withholding approval of the proposed sale affords more protection of the taxpayers than does providing approval.” Miller said the sale didn’t make economic sense to the Treasury. “Net net, this would look negative to the shareholder and that’s who Treasury is supposed to be representing,” Miller said. A Goldman Sachs spokesman, Lucas van Praag , declined to comment, as did a Fannie Mae spokesman, Brian Faith . Fannie Mae has posted $120.5 billion in net losses over the past nine quarters and requested $59.9 billion in Treasury aid. Tax Benefits Fannie Mae has accumulated about $5.2 billion in tax credits for investing in low-income housing, and has said in previous filings that it is “not currently recognizing a majority of the tax benefits associated with tax credits.” The company said Nov. 5 that it will need to write down the $5.2 billion investment to zero if “we no longer have the intent and ability to sell or otherwise transfer” the low- income housing tax credits, which are derived from investments in affordable rental housing. McLean, Virginia-based rival Freddie Mac, which is also operating under federal conservatorship, said in a separate SEC filing yesterday that it has about $3.4 billion in tax credits it may need to write down. “If we are not able to execute sales or other transactions in order to realize the benefits of these investments or do not receive regulatory approval for such transactions, we may record significant other-than-temporary impairment,” Freddie Mac said. To contact the reporter on this story: Dawn Kopecki in Washington at dkopecki@bloomberg.net

Read the full article →

Rancher Energy Corp. Files for Chapter 11 Reorganization; Normal Operations Continuing and Unaffected

October 28, 2009

Rancher Energy Corp. Plans to Continue to Operate and Provide Pay and Benefits to Employees

Read the full article →

Sima Gandhi: Why the Savings From Health Care Reform Are Underappreciated

October 12, 2009

The lack of a whole-hearted, landslide, public embrace of health reform is surprising considering that unless your family earns over $250,000, reform costs you nothing and, the President’s health care plan, if enacted, is estimated to increase the income of the average family of four by about $10,000 in 2030. One part of the explanation for public reluctance to embrace reform may be explained by behavioral economics. Behavioral economists have found that people in most situations: Undervalue future money and overvalue money now, Focus on losses over gains, and Prefer the status quo over change. How does this play out in health care? Let’s consider each of these behavioral factors in turn. The first, undervaluation of the future, is called hyperbolic discounting. A classic example of hyperbolic discounting is credit card debt. A shopping spree generates benefits today for costs that occur in the future; because the costs occur in the future, shoppers tend to undervalue them. Accordingly, people tend to prefer actions that produce benefits today with future costs over those that produce costs today with future benefits. Hyperbolic discounting also offers an explanation for low rates of savings and investment in the United States. Savings and investing both involve costs today but benefits are not realized until far off in the future. Healthcare reform is like investing; it requires up front costs for future benefits. Reform benefits families by increasing income. It also, among other benefits, saves families money by lowering premiums, copayments, and out of pocket expenses. Some estimates project families will save $3,759 in premiums in 2020 compared to what they would pay without reform. Despite these real financial savings, people may undervalue the benefits because they will occur in the future. Just as future benefits of change are discounted, so too are the costs of continuing the current health care system. Studies show that without reform a family of four can expect to pay almost $24,000 in premiums by 2020 . Other costs of the current system include benefit reductions, denial of care, and less coverage – these additional costs may not have a price tag on them but they are just as real as the benefits of reform. Yet, research suggests that the public may undervalue these costs because they are still to come. Then there’s loss aversion, which helps explain why people feel anxious about reform despite its benefits. Studies indicate that people experience greater unhappiness from paying out a $1 than they do pleasure from receiving a $1. In short, people don’t get as excited about gains as they get worried about losses. So even though healthcare reform doesn’t cost most taxpayers anything and is revenue-neutral which means it doesn’t affect the federal budget, the fact that it does cost something generates anxiety. Think about the example of the $1. A person that spends a dollar in the morning but gets a dollar back at dinner will be less happy than a person that doesn’t spend or get anything at all – even though at the end of the day they both have the same amount of money. Loss aversion tells us that contrary to logic, a dollar in is not the same as a dollar out. Even people who aren’t satisfied with the current healthcare system will feel anxious about change and can be very susceptible to arguments that they may lose something they value. Finally, change is hard. Behavioral economics explains aversions to change through the endowment effect, or the preference for things simply because they belong to you. The following classic experiment illustrates how the endowment effect works. In it, some students in a class were given coffee mugs and asked to name a selling price. Others in the class were asked how much they would pay to buy the mugs. Rational people should value identical mugs equally. Researchers found that was not the case. Instead of valuing the mugs equally, people with the mugs demanded more than twice as much as the people without the mugs. Simply possessing the mugs increased their value. When it comes to health care reform, many people may want to keep the current system because it’s what they have now — and they value it. The American people have two choices. Implement healthcare reform now, when the future benefits outweigh the current costs — even though it may feel like the costs are higher than the benefits. Or wait as rising healthcare costs slowly drain our bank accounts. Either way, the need for reform is real. Let’s get rational and do it.

Read the full article →

Macy’s Profit Exceeds Estimates After Retailer Reduces Costs, Inventories

August 12, 2009

By Cotten Timberlake Aug. 12 (Bloomberg) — Macy’s Inc. , the second-biggest U.S. department-store chain, increased its full-year profit forecast and posted earnings that beat analysts’ estimates after it cut expenses and inventories. Net income fell to $7 million, or 2 cents a share, in the second quarter ended Aug. 1, from $73 million, or 17 cents, a year earlier, the Cincinnati-based company said in a statement distributed on Business Wire today. Before restructuring costs, per-share profit beat analysts’ estimates by 3 cents. Macy’s expenses fell and the chain reduced its inventories by 7.5 percent from a year ago. Sales declined as consumers held back on non-essential purchases in the face of job losses and lower home values. “We are seeing the benefits of the restructuring the company has undertaken, which are really materializing in terms of cost savings,” Matt Arnold , an analyst with Edward Jones & Co., said in a telephone interview yesterday. “It’s a combination of that and really tight inventory management, so they don’t have to mark down to blow out inventory at any cost.” Arnold, based in Des Peres, Missouri, recommends holding Macy’s shares. Macy’s raised its forecast for annual profit before restructuring costs to as much as 80 cents a share from a maximum of 55 cents predicted earlier. Profit before one-time restructuring costs was 20 cents a share. That compares with an average of 17 cents in a Bloomberg survey of 13 analysts. Macy’s advanced 27 cents, or 1.7 percent, to $15.74 at 8:06 a.m. before the start of New York Stock Exchange composite trading. Before today, the shares gained 49 percent this year. To contact the reporter on this story: Cotten Timberlake in Washington at ctimberlake@bloomberg.net

Read the full article →

Veteran Employee Benefits Executive Vicki Cullen Joins ClearPoint as VP to Service Portland, Oregon-Area Accounts

August 10, 2009

With More Than 23 Years of Experience, Cullen Specializes in Meeting the Benefits Needs of Diverse Mid-Size Clients

Read the full article →